Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Titel:
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Auteur:
Michallet, Anne-Sophie Dilhuydy, Marie-Sarah Subtil, Fabien Rouille, Valerie Mahe, Beatrice Laribi, Kamel Villemagne, Bruno Salles, Gilles Tournilhac, Olivier Delmer, Alain Portois, Christelle Pegourie, Brigitte Leblond, Veronique Tomowiak, Cecile de Guibert, Sophie Orsini, Frederique Banos, Anne Carassou, Philippe Cartron, Guillaume Fornecker, Luc Mathieu Ysebaert, Loic Dartigeas, Caroline Truchan Graczyk, Malgorzata Vilque, Jean P Aurran, Thérèse Cymbalista, Florence Lepretre, Stéphane Lévy, Vincent Nguyen-Khac, Florence Le Garff-Tavernier, Magali Aanei, Carmen Ticchioni, Michel Letestu, Rémi Feugier, Pierre